Treatments aimed at stimulation of the BDNF receptor, tropomyosin receptor-kinase B (TrkB), may prove clinically beneficial in counteracting the effects of METH, at least on PPI, and this may extend to psychosis and schizophrenia more generally. The gene discussed is NTRK2; the disease is schizophrenia.